Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates

Company Performance - Biodesix, Inc. reported a quarterly loss of $0.08 per share, which aligns with the Zacks Consensus Estimate, an improvement from a loss of $0.14 per share a year ago [1] - The company posted revenues of $17.96 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 7.19%, but showing an increase from $14.82 million year-over-year [2] - Over the last four quarters, Biodesix has surpassed consensus EPS estimates three times, while it has topped consensus revenue estimates only once [2][3] Stock Performance - Biodesix shares have declined approximately 76.5% since the beginning of the year, contrasting with the S&P 500's decline of only 0.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $22.3 million, and for the current fiscal year, it is -$0.22 on revenues of $92.75 million [7] Industry Outlook - The Medical Services industry, to which Biodesix belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Biodesix's stock performance [5][6]